Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Cerebrolysin vs C-Max (Cerebrolysin variant)
An educational, source-based comparison of Cerebrolysin and C-Max (Cerebrolysin variant) — how each peptide works, what it's researched for, and what to know before going deeper.
Porcine-derived peptide mixture researched in neurologic recovery.
A mixture of low-molecular-weight peptides and amino acids derived from purified porcine brain tissue. Research suggests neurotrophic-like activity mimicking BDNF, NGF, and GDNF signaling.
- Ischemic stroke recovery
- Traumatic brain injury
- Vascular dementia and Alzheimer's adjunct
- • Approved in many countries; not FDA-approved in the US.
- • Mixture composition is not fully characterized.
Concentrated neuropeptide fraction for cognitive support research.
A concentrated fraction of cerebrolysin containing specific neuropeptide sequences. Research suggests enhanced delivery of neurotrophic factors supporting synaptic maintenance and neurogenesis.
- Post-stroke cognitive recovery
- Vascular cognitive impairment
- Traumatic brain injury rehabilitation
- • Not FDA-approved in the US; approved in select countries.
- • Requires medical supervision for IV administration.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Cerebrolysin | Cerebrolysin in acute ischemic stroke (CARS trial) | Stroke | 2016 | Improved early motor recovery in combination with rehabilitation. |
| C-Max (Cerebrolysin variant) | Concentrated neuropeptide fractions in stroke rehabilitation | Neurorehabilitation and Neural Repair | 2018 | Improved functional outcomes in post-stroke patients receiving neuropeptide therapy. |
Side-effect & safety grid
- Approved in many countries; not FDA-approved in the US.
- Mixture composition is not fully characterized.
- Not FDA-approved in the US; approved in select countries.
- Requires medical supervision for IV administration.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Cerebrolysin vs C-Max (Cerebrolysin variant) — Key differences
- Class: Cerebrolysin is classified as Neurotrophic · Mixture, while C-Max (Cerebrolysin variant) is Nootropic · Neurotrophic.
- Primary research focus: Cerebrolysin — ischemic stroke recovery; C-Max (Cerebrolysin variant) — post-stroke cognitive recovery.
- Tag: Cognition · Neuroprotection vs Cognition.